Next-generation sequencing

Next-generation sequencing (NGS) can deliver unprecedented insights, unraveling the intricacies of the genome and transcriptome in biomarker research, gene expression studies, viral epidemiology and disease surveillance, as well as comprehensive genomic profiling to identify variants implicated in cancer and other diseases. However, challenges such as workflow optimization, customization and data analysis and interpretation can hinder progress.

Uncover more biology with NGS technology

Navigate the complexity of the NGS world with ease by partnering with QIAGEN. Benefit from extensive expertise, tailored solutions and market-leading informatics so you can achieve:

• Accurate results from even the most challenging of samples
• Faster turnaround times using streamlined and optimized workflows
• Meaningful insights from complex NGS data

SARS-CoV-2 epidemiology and metatranscriptomics

Deeper, more holistic insights into SARS-CoV-2 biology – from viral strain evolution and phylogenetics to metatranscriptomics and gene expression – can accelerate vaccine and drug discovery research to combat the COVID-19 pandemic. Explore the full spectrum of our high-performance NGS solutions and integrated bioinformatics pipelines that collectively drive a greater understanding of the multiple facets of SARS-CoV-2 biology.

Accelerating human and bacterial co-expression studies with high-quality RNA-seq data

Dr. Marie Adams from the Van Andel Institute discusses how QIAseq FastSelect technology helped conquer the challenges of generating high-quality RNA-seq data for human and bacterial co-expression studies from the same RNA sample.

Increasing RNA-seq sensitivity in cancer research

Researchers from the University of Houston discuss how powerful QIAseq FastSelect rRNA removal technology transformed their research, allowing them to retrieve useful RNA-seq data from FFPE RNA.

Defending against cancer by manipulating the immune system using NGS technology

Dr. Nathalie Labarrière from the University of Nantes describes her work using QIAseq Immune Repertoire RNA Library Kits to target colon cancer and melanoma tumors in new immuno-oncology therapies.

Driving insights into pancreatic cancer risk using custom NGS panels

Dr. Fergus Couch from the Mayo Clinic discusses how QIAseq Targeted DNA Panels played a vital role in a longitudinal case-control study on the risk of pancreatic cancer.

Ensuring uniform coverage enables heterozygous mutation detection in cancer research

Dr. Egbert Schulze from the Endocrinology and Nuclear Medicine Community Practice, Heidelberg, discusses how the all-enzymatic QIAseq FX workflow enabled uniform coverage and helped him achieve reliable sequencing results in his research.